AptaBio Therapeutics (293780) Fundamentals 2026 — Revenue Analysis | SniperIQ
AptaBio Therapeutics (293780) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩118.8B, trading at ₩4230.00 on the KOE. This SniperIQ fundamentals page covers AptaBio Therapeutics's valuation, profitability (net margin -473.1%), revenue (₩3.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is AptaBio Therapeutics's market cap?
AptaBio Therapeutics (293780) has a market capitalization of approximately ₩118.8B, trading at ₩4230.00 on the KOE. Market cap moves with the live share price.
What is AptaBio Therapeutics's P/E ratio?
AptaBio Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is AptaBio Therapeutics?
AptaBio Therapeutics runs a net profit margin of -473.1%, a gross margin of 38.1%, and an operating margin of -443.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does AptaBio Therapeutics generate?
AptaBio Therapeutics reported revenue of ₩3.7B for fiscal year 2025, with net income of -₩16.3B and earnings per share (EPS) of -607.49. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does AptaBio Therapeutics pay a dividend?
AptaBio Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is AptaBio Therapeutics financially healthy?
AptaBio Therapeutics carries a debt-to-equity ratio of 0.11x and a current ratio of 1.72x, with a market beta of 0.82. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is AptaBio Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For AptaBio Therapeutics (293780) the key facts are: market cap ₩118.8B, revenue ₩3.7B, 52-week range 3870-10890. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track AptaBio Therapeutics's full fundamentals live
Get AptaBio Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.